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Introduction
Menopause is the permanent cessation of the menstrual 
cycles following the loss of ovarian reproductive function 
and is a natural physiological process related to aging.1 The 
postmenopausal period is clinically and retrospectively di-
agnosed with the following amenorrhea for more than 12 
months.
There is evidence of a worsening quality of life (QOL) af-
ter menopause, especially in relation to the presence of cli-
macteric symptoms, their frequency and intensity.1 Among 
the climacteric symptoms that affect QOL are insomnia (INS) 
and musculoskeletal pain (MSP).
Epidemiological investigations focusing on the postmeno-
pause stage worldwide show an alarming prevalence of MSP2 
and INS,3 although the different methods used to evaluate 
INS and the frequent lack of a clinical diagnosis hamper the 
comparison among the studies. As women age, both sleep 
disturbances and pain complaints tend to increase. 
INS seems to influence the onset and level of MSP in dif-
ferent populations,4 although most studies focus on both 
sexes and different age ranges, rather than specifically in 
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postmenopausal women. The co-occurrence of poor sleep 
quality, pain, and mood symptoms, such as anxiety and 
depression is evidenced in the literature and presented as a 
cluster of symptoms in women.5 However, there is no evi-
dence in the literature about the association between chronic 
MSP complaints and INS in postmenopausal women and 
its characteristics regarding MSP, menopausal and mood 
symptoms, sleep and and QOL. We also aimed to examine 
the predictor factors for menopausal symptoms and QOL. 
Materials and Methods
1. Ethical aspects
The present study was approved by the Ethics Commit-
tee of the Universidade Federal de São Paulo (CEP/UNIFESP 
#786.299/2014). Recruitment of general women took place 
between February 2015 and October 2016.
2. Recruitment criteria
A total of 355 women were assessed for eligibility to take 
part in the study, with 62 being selected after the evaluation 
of the inclusion and exclusion criteria (Fig. 1). The inclu-
sion criteria consisted of being women aged 50 to 65 years; 
15
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17
Insomnia + musculoskeletal
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280
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Questionnaires, pain and
vasomotor symptoms diaries
+
Polysomnography (n = 43)
+
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355
Women assessed for eligibility
51 declined to participate
39 hypnotic or sedative medication
31 BMI>30 kg/m
29 antidepressant medication
23 hormone replacement therapy
21 age <50 or >65 years
19 oophorectomy
16 non-pharmacological treatment for pain
13 menopausal transition
12 analgesic muscle relaxant medication
8 other sleep disturbances
3 physiotherapy for pain
3 isoflavone
3 fibromyalgia
2 herbal medicines
2 chemotherapy
2 shift workers
1 herniated disc
1 HIV+
1 Illiterate
2
62
Enrolled in the study
Clinical evaluation by a physician
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13
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4 AHI >15/h
3 AHI >15/h + PLMi >15/h + clinical
repercussion
Fig. 1. The consolidated standards 
of reporting trials flow chart. BMI: 
body mass index, HIV+: human 
immunodeficiency virus-positive, 
FSH: follicle-stimulant hormone, 
AHI: apnea-hypopnea index, PLMi: 
periodic limb movements index.
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present at least 1 year of amenorrhea; follicle-stimulating 
hormone concentrations ≥30 mIU/mL; undergo a clinical 
consultation for confirmation of menopause diagnosis; to not 
have taken hormonal therapy in the previous 6 months; and 
to not be obese (body mass index [BMI] < 30 kg/m2). As ex-
clusion criteria, we considered: high risk for sleep disordered 
breathing, assessed by the Stop-Bang questionnaire;6 self-
report of uncontrolled clinical; major neurologic, orthopedic 
and rheumatologic diseases, autoimune disorders or condi-
tions that could influence pain; psychiatric disorders; use of 
psychoactive drugs such as hypnotic, antidepressants, anx-
iolytics, benzodiazepines and central nervous system stimu-
lants; attending psychotherapy, physiotherapy or treatments 
for INS or pain; shift work; illiteracy; and the presence of 
other sleep disorders diagnosed by polysomnography (PSG) 
exam (narcolepsy, obstructive sleep apnea evidenced by an 
apnea-hypopnea index (AHI) ≥15/hr, periodic limb move-
ments (PLM) index ≥15/hr and parasomnias). 
3. Sociodemographic and clinical assessment
Participants provided sociodemographic data and reported 
any comorbidities on their first visit. Weight and height were 
assessed in the first visit, allowing for the calculation of 
BMI (Kg/m2). All volunteers completed questionnaires upon 
enrollment. On their second visit, volunteers underwent a 
laboratory PSG exam on a scheduled night followed by a 
blood sample collection in the following morning. On the 
third visit, volunteers with an INS Severity Index ≥157 had 
a clinical consultation to confirm their INS diagnosis. 
4. Postmenopausal assessment
The postmenopausal stage was classified according to 
Stages of Reproductive Aging Workshop (STRAW) criteria 
into early, which covers the first 8 years since menopause; 
and late, which covers the subsequent period.8 
5. Questionnaires
Brief Pain Inventory - MSP severity and MSP interference 
with daily function.
This questionnaire was used to evaluate the severity and 
interference of MSP.9 The answers are distributed on a nu-
merical scale from 0-10, with 0 representing “does not in-
terfere” and 10 representing “interferes completely”. 
6. Pain visual analog scale (VAS) - pain intensity
Participants completed 3 times a day over 10 days a pain 
diary, composed of an average pain rating on a VAS (0 “no 
pain”, 10 “worst pain imaginable”).10 VAS scores were aver-
aged across days for each period to assess the intensity of 
chronic MSP during the day. 
7. Menopausal symptomatology
The Menopause Rating Scale accessed menopausal symp-
toms in 3 domains: somatic, psychological and urogenital.11
8. Quantification of vasomotor symptoms
Participants reported the number of hot flashes and night 
sweats before going to bed of the previous night daily during 
10 days. The number of vasomotor symptoms was averaged 
across days. 
9. QOL
The World Health Organization QOL Questionnaire, brief 
form (WHOQOL-BREF) assesses the individual’s perception 
in a general index, independently of its 4 domains: physical, 
psychological, social relations and environment. The score 
ranges from 0 to 100, the closer to 100, the better is QOL 
perception.12
10. Mood symptoms
The Beck Anxiety Inventory investigates common symp-
toms of anxiety, and results range from 0 to 63: 0 to 7 is 
interpreted as a “minimal level of anxiety”; 8 to 15 as “mild”; 
16 to 25 as “moderate”; and 26 to 63 as “severe anxiety 
symptoms”.13 
The Beck Depression Inventory examines episodes of de-
pression. It ranges from 0 to 63; 0 to 9 is interpreted as a 
“no depression symptoms or minimal”; 10 to 18 as “mild-
moderate”; 19 to 29 as “moderate to severe”; 30 to 63 as 
“severe depression symptoms”.14
11. Sleep quality and daytime sleepiness
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated 
questionnaire that assesses sleep quality and disturbances 
over a 1-month period. A PSQI ≤ 5 indicates good sleep 
quality, while > 5 is associated with poor sleep quality, 
and > 10 indicates sleep disturbances.15
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Epworth Sleepiness Scale was used to evaluate excessive 
daytime sleepiness. The score ranges from 0 to 24, and 0 
to 9 indicates “no sleepiness symptoms”, while > 9 may be 
“suggestive of daytime sleepiness”.16 
12. PSG
We used PSG for assessment of objective sleep patterns 
and to exclude volunteers with other comorbid sleep dis-
orders from the study. All participants underwent a basal 
PSG, performed using a digital system (EMBLA® N7000; 
Embla Systems Inc., Broomfield, CO, USA) during their 
usual sleep time. The following physiological variables were 
evaluated: electroencephalogram (EEG), electrooculogram 
(bilateral), electromyogram, electrocardiogram (derivation D2 
modified), airflow detection by a thermocouple and by nasal 
pressure, respiratory effort using thoracic and abdominal x-
trace belts, snoring and body position by EMBLA sensors, 
percutaneous oxygen saturation (SpO2) and pulse rate by an 
EMBLA oximeter. All PSG were visually scored by a reg-
istered and trained PSG technologist, blinded to group al-
location. All sleep stages, EEG arousals, leg movements and 
respiratory events were scored according to the guidelines of 
the American Academy of Sleep Medicine.17
13. Definition of groups
Participants were categorized into 4 groups: control, post-
menopausal healthy controls without MSP and INS; MSP, 
volunteers presenting chronic MSP pain complaints without 
INS, assessed using the Nordic Musculoskeletal Question-
naire;18 INS, participants presenting an INS disorder diag-
nosis without MSP (ISI ≥ 15 had a clinical consultation to 
confirm the INS diagnosis according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition criteria19), 
and INS + MSP, volunteers having both conditions.
14. Sample size calculation
The sample size was calculated for 80% power, an effect 
size of 0.72 with Cohens’ d and an α error of 0.05. For the 
subjective parameters (pain VAS as outcome), the required 
sample size was 12 per group and a total of 48 volunteers. 
The sample size calculation was made using G * Power 
software version 3.1.9.2 (Franz Faul; Universitat Kiel, Kiel, 
Germany).
15. Statistical analysis
Continuous variables were analyzed through a two-
way analysis of variance (ANOVA). The distributions were 
evaluated for normality and homogeneity of variances by 
Shapiro-Wilk and Levene’s test, respectively. Based on this 
assessment, the following variables were square root trans-
formed, to satisfy the models’ normality assumptions of dis-
tributed residuals: time since menopause, pain interference, 
sleep latency, rapid eye movement (REM) sleep latency, wake 
after sleep onset (WASO), sleep efficiency, non-REM (NREM; 
NREM stage N1 sleep, NREM stage N2 sleep, arousal index, 
respiratory disturbance index, AHI, PLM and number of 
vasomotor symptoms. Pearson’s χ2 test was used to verify 
associations between categorical variables. Generalized lin-
ear models with Gamma or Tweedie distributions were used 
to assess the associated factors for menopausal symptom-
atology and QOL continuous variables, and was followed by 
Sidak post hoc analysis when necessary. All analyses were 
conducted using SPSS version 18 software (SPSS Inc., Chi-
cago, IL, USA). Statistical significance was set at P ≤ 0.05.
Results
From a total of 75 women who entered the protocol, 62 
were eligible and were allocated into 4 groups: control, MSP, 
INS, and INS + MSP (Fig. 1). The sample was homogeneous 
as demonstrated in Table 1, except for age, with the INS 
group being older than all other groups (F = 3.88, df = 1, P = 
0.05), and the presence of hypertension in the INS group 
was significantly higher compared to the other groups (χ2 = 
9.1; df = 1; P = 0.03).
INS and MSP were individually and independently as-
sociated with higher MSP severity (F = 10.31, df = 1, P = 
0.002; F = 15.27, df = 1, P = 0.000; respectively, Table 2). 
A similar pattern was observed for the interference of pain 
with daily function (F = 10.53, df = 1, P = 0.005; F = 26.96, 
df = 1, P = 0.000) and its domains, such as general activ-
ity (F = 5.4, df = 1, P = 0.02; F = 12.01, df = 1, P = 
0.001), mo od (F = 8.23, df = 1, P = 0.006; F = 8.86, df = 1, P = 
0.004), walking ability (F = 5.03, df = 1, P = 0.03; F = 7.85, df = 1, 
P = 0.007), sleep (F = 5.41, df = 1, P = 0.02; F = 18.72, df = 1, P = 
0.00) and ability to appreciate life (F = 10.89, df = 1, P = 0.002; 
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Table 1. Mean ± standard deviation or frequency of sociodemographic and clinical characteristics of control, musculoskeletal pain, 
insomnia, and insomnia + musculoskeletal pain groups (n = 62)
 Control(n = 15)
MSP 
(n = 15)
INS 
(n = 15)
INS + MSP 
(n = 17)
P value
INS * MSP INS MSP
Age (years)* 58.8 ± 3.9 58.9 ± 3.6 59.9 ± 3.0‡ 56.2 ± 4.5 0.05 0.42 0.07
BMI (kg/m2)* 24.8 ± 3.32 26.3 ± 2.64 25.6 ± 3.02 26.11 ± 2.37 0.52 0.69 0.16
Marital status† 0.52
   Single 2 (13.3) 4 (26.7) 2 (13.3) 3 (17.6)
   Married 6 (40.0) 6 (40.0) 4 (26.7) 9 (52.9)
   Divorced/Separated 4 (26.7) 5 (33.3) 5 (33.3) 4 (23.5)
   Widowed 3 (20.0) 0 (0.0) 4 (26.7) 1 (5.9)
Ethnicity† 0.48
   White 10 (66.7) 11 (73.3) 7 (46.7) 11 (64.7)
   Black 0 (0.0) 1 (6.7) 3 (20.0) 2 (11.8)
   Yellow 2 (13.3) 1 (6.7) 0 (0.0) 2 (11.8)
   Mulatto 3 (20.0) 1 (6.7) 3 (20.0) 2 (11.8)
   Indian 0 (0.0) 1 (6.7) 2 (13.3) 0 (0.0)
Income (R$, monthly)† 0.33
   < 1 to 2 MS 2 (13.0) 3 (20.0) 4 (26.7) 1 (5.9)
   ≥ 2 to 5 MS 6 (40.0) 9 (60.0) 10 (66.7) 10 (58.8)
   ≥ 5 to 10 MS 3 (20.0) 1 (6.7) 0 (0.0) 1 (5.9)
   ≥ 10 MS 4 (26.7) 2 (13.3) 1 (6.7) 5 (29.4)
Education level† 0.82
   High school 1 (6.7) 3 (20.0) 2 (13.3) 2 (11.8)
   Elementary school 5 (33.3) 2 (13.3) 7 (46.7) 5 (29.4)
   Higher education 6 (40.0) 7 (46.7) 4 (26.7) 6 (35.3)
   Postgraduate 3 (20.0) 3 (20.0) 2 (13.3) 4 (23.5)
Current smoking† 0 (0.0) 2 (13.3) 0 (0.0) 1 (5.9) 0.27
Time since menopause (years)* 8.9 ± 4.48 9.1 ± 3.99 9.5 ± 5.09 8.0 ± 7.23 0.56 0.85 0.63
Type of menopause† 0.86
   Spontaneous 13 (86.7) 14 (93.3) 14 (93.3) 16 (94.1)
   Surgical 2 (13.3) 1 (6.7) 1 (6.7) 1 (5.9)
Children† 11 (73.3) 10 (66.7) 4 (26.7) 13 (76.5) 0.94
Comorbidities†
   Hypertension 5 (33.3) 4 (26.7) 11 (73.3)§,¶ 5 (29.4)∥ 0.03
   Diabetes mellitus 3 (20.0) 2 (13.3) 5 (33.3) 3 (17.6) 0.56
   Osteoporosis 0 (0.0) 2 (13.3) 0 (0.0) 3 (17.6) 0.15
The data is presented as mean ± standard deviation or n (%). All volunteers stated they had not used alcohol in the previous 3 months
*Two-way analysis of variance
†Pearson's χ2 test
‡P < 0.05 compared to other groups
§P < 0.05 compared to control
∥P < 0.05 compared to INS
¶P < 0.05 compared to MSP
BMI: body mass index, MS: minimal salary in Brazilian currency (Reais), MSP: musculoskeletal pain, INS: insomnia
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F = 6.99, df = 1, P = 0.01). For the working ability and 
relationships with other people domains, we observed an 
association with MSP only, worsening these domains (F 
= 7.86, df = 1, P = 0.007; F = 12.71, df = 1, P = 0.001; re-
spectively, Table 2). 
Regarding the intensity of pain recorded in a 10-day 
pain diary, as expected the presence of MSP, independently 
of INS, was associated with increased pain intensity in all 
3 periods evaluated: upon waking (F = 20.33, df = 1, P = 
0.000), at midday (F = 20.13, df = 1, P = 0.000) and before 
going to bed (F = 27.24, df = 1, P = 0.000). At midday, the 
INS groups presented increased pain compared to non-INS 
groups (F = 5.22, df = 1, P = 0.02; Table 2). Addition-
ally, the INS + MSP group presented a higher frequency of 
women reporting 3 or more pain sites (88.2%) compared to 
all the other groups (Table 2). MSP was a result of the fol-
lowing disorders: plantar fasciitis, elbow and shoulder ten-
dinitis, hip and shoulder bursitis, carpal tunnel syndrome, 
low back pain, cervical spine pain, ankylosing spondylitis, 
temporomandibular disorder, and hand, shoulder, arm, 
back, knee, hip, leg and foot pain.
INS with MSP and INS alone were associated with higher 
menopausal symptoms (F = 10.76, df = 3, P = 0.000; Fig. 
2). In relation to the Menopause Rating Scale domains, the 
somatic (F = 10.52, df = 3, P = 0.000), and the psychologic 
(F = 9.98, df = 3, P = 0.000) domains presented the same 
pattern (Fig. 3). We found no significant statistical differ-
ence among groups in the urogenital domain (F = 1.19, df = 3, 
P = 0.32).
In relation to mood symptoms, INS alone (F = 9.20, df = 
1, P = 0.04) and MSP alone increase anxiety symptoms (F = 
5.33, df = 1, P = 0.02). Regarding depression symptoms, no 
statistical differences were observed among the groups (F = 
0.53, df = 1, P = 0.47; Table 3).
No significant differences were observed among the 
groups regarding vasomotor symptoms (F = 0.67, df = 1, 
P = 0.42; Table 3). 
In relation to sleep, a significant interaction between INS 
and MSP was also observed for sleep quality (F = 83.06, 
df = 1, P = 0.001), as the INS group presented worse sleep 
quality compared to all other groups. No statistical dif-
ferences were found for daytime sleepiness among the 
groups (F = 0.06, df = 1, P = 0.81; Table 3). 
A significant interaction effect between INS and MSP was 
observed for PLM (F = 4.20, df = 1, P = 0.05), showing that 
the INS group had the highest PLM index compared to other 
groups. The presence of INS was associated with increased 
WASO and AHI, and decreased mean SpO2, independent of 
chronic MSP (F = 5.61, df =1, P = 0.02; F = 7.16, df = 1, 
P = 0.001; F = 4.85, df = 1, P = 0.03; respectively Table 4). 
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groups. Data analyzed through analysis of variance. *P < 0.05 
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Rating Scale score is classified as 0 to 4: asymptomatic or scarce 
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chological domains derived from the Menopause Rating Scale 
among control, musculoskeletal pain (MSP), insomnia (INS), and 
INS + MSP groups. Data analyzed through analysis of variance. 
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Menopause Rating Scale score is classified as 0 to 4: asymptomatic 
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Regarding QOL, the results showed that INS alone (F 
=14.08, df = 1, P = 0.00) and an MSP alone (F = 4.18, df = 1, 
P = 0.05) worsened QOL general index. The physical domain 
of QOL followed the same pattern as INS (F = 20.13, df = 1, 
P = 0.00) and MSP (F = 13.22, df = 1, P = 0.01) were inde-
pendently associated with worse QOL. The presence of INS 
alone was associated with decrease in both psychological and 
environmental domains of QOL (F = 8.01, df = 1, P = 0.01; 
F = 5.28, df = 1, P = 0.02; respectively, Table 3). 
As shown in Table 5, the generalized linear model showed 
increased symptoms of anxiety and depression, as well as 
INS severity, were positively associated with higher meno-
pausal symptoms. Each 1-unit increase in anxiety symp-
toms score was associated with a 50% addition in the meno-
pausal symptoms score. Each 1-unit increase in depressive 
symptoms score and INS severity score were associated with 
a 2.1-fold and 3.6-fold increase of menopausal symptoms 
score, respectively.
Regarding the predictor factors of QOL in the whole 
sample of women included in the current study, the results 
showed that each 1-unit increase of depressive symptoms 
score was associated with a 10% decrease in QOL. Addition-
ally, each 1-unit increase in pain interference score was as-
sociated with a 30% decrease in QOL (Table 6).
Discussion
This is the first study, to the best of our knowledge, to 
show the characteristics of INS + MSP combined on in-
Table 3. Mean ± standard deviation of insomnia severity index, sleep quality, sleepiness, symptoms of anxiety and depression, habitual 
physical activity, quality of life, and vasomotor symptoms among control, musculoskeletal pain, insomnia, and insomnia + musculoskeletal 
pain groups (n = 62)
Control
(n = 15)
MSP
(n = 15)
INS
(n = 15)
INS + MSP
(n = 17)
P value
INS * MSP INS MSP
Pittsburgh Sleep Quality Index* 6.3 ± 2.32 9.7 ± 3.15 13.1 ± 2.18‡‡ 11.7 ± 2.88 0.001 0.000 0.15
Epworth Sleepiness Scale† 7.4 ± 5.91 8.2 ± 3.67 8.3 ± 3.60 8.6 ± 6.02 0.81 0.62 0.66
Beck Anxiety Inventory‡ 7.5 ± 9.24 12.6 ± 5.37†† 14.1 ± 6.40** 18.8 ± 10.69**,†† 0.93 0.04 0.02
Beck Depression Inventory§ 9.6 ± 6.40 14.5 ± 6.85 14.3 ± 7.79 16.5 ± 8.67 0.47 0.09 0.07
Quality of life, WHOQOL-Bref (%)∥
   Quality of life general index 68.8 ± 13.19 60.5 ± 12.17†† 55.5 ± 7.83** 51.9 ± 11.84**,†† 0.42 0.000 0.05
   Physical domain 79.6 ± 12.99 60.4 ± 19.27†† 57.1 ± 13.15** 47.7 ± 15.37**,†† 0.21 0.000 0.01
   Psychological domain 61.6 ± 20.64 64.0 ± 15.80 58.6 ± 9.28** 54.5 ± 15.74** 0.84 0.01 0.19
   Social relations domain 69.5 ± 14.57 57.8 ± 17.09 53.9 ± 14.77 52.3 ± 15.47 0.80 0.14 0.54
   Environmental domain 64.7 ± 17.26 59.8 ± 16.90 52.5 ± 11.40** 53.2 ± 17.72** 0.51 0.02 0.61
No. of vasomotor symptoms¶ 1.1 ± 1.87 1.9 ± 2.39 2.3 ± 3.19 1.7 ± 1.71 0.42 0.24 0.86
Two-way analysis of variance
*0-4: good sleep, 5-10: bad sleep, ≥10: requires medical assistance
†0-9: no sleepiness symptoms, ≥10: suggestive of daytime sleepiness and requires medical assistance
‡0-7: minimum degree of anxiety, 8-15: mild anxiety, 16-25: moderate anxiety, 26-63: severe anxiety
§0-9: no depression symptoms, 10-15: mild depression symptoms, 16-19: mild to moderate depression symptoms, 20-30: moderate to 
severe depression symptoms, >30: severe depression symptoms
∥Score range from 0 to 100, and closer to 100, better quality of life
¶Mean of 10 days recording of day and night vasomotor symptoms
**P < 0.05 compared to INS-free groups
††P < 0.05 compared to MSP-free groups
‡‡P < 0.05 compared to all other groups
WHOQOL-Bref: brief form of the World Health Oragnization Quality of Life, MSP: musculoskeletal pain, INS: insomnia
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creased anxiety, worse MSP severity and higher interfer-
ence with daily function, more MSP intensity at midday, 
increased number of MSP sites, more sleep fragmentation 
(WASO) and worse QOL in postmenopausal women. 
There is strong evidence about the sleep-pain interaction 
and its bidirectionality in the general population. INS, in-
dependently of MSP, has been shown to be associated with 
MSP severity and MSP interference in most of its domains. 
Chronic MSP conditions have been linked to disturbed sleep10,11 
and short sleep duration (< 360 min).4 
INS alone was associated with increased pain intensity at 
midday. A study by Tang and colleagues,20 in the general 
population, showed that sleep helped to reduce pain inten-
sity. A possible hypothesis for this is that sleep deprivation 
increases plasma levels of cortisol which is responsible for 
increased pain sensitivity. Cortisol concentrations start to 
decline from midday and reach their lowest concentrations 
in the late evening and during the early part of the sleep 
period.21 In addition, the presence of restorative sleep seems 
to reduce chronic generalized pain22 and in our sample, this 
Table 4. Mean ± standard deviation of objective sleep pattern among control, musculoskeletal pain, insomnia, and insomnia + 
musculoskeletal pain groups (n = 43)
Control
(n = 10)
MSP
(n = 11)
INS
(n = 12)
INS + MSP
(n = 10)
P value
INS * MSP INS MSP
TST (minutes) 337.8 ± 43.83 348.2 ± 55.35 321.7 ± 67.84 328.4 ± 56.26 0.92 0.31 0.63
Sleep latency (minutes)* 32.6 ± 43.59 42.7 ± 55.02 38.4 ± 28.08 18.1 ± 11.05 0.19 0.74 0.47
REM sleep latency (minutes)* 138.2 ± 58.80 111.1 ± 79.03 121.2 ± 81.39 131.0 ± 96.83 0.37 0.92 0.58
Sleep efficiency (%)* 76.5 ± 11.36 78.1 ± 13.30 71.2 ± 11.63 73.3 ± 11.66 0.93 0.20 0.65
Stage NREM N1 (%)* 10.4 ± 2.13 13.5 ± 8.00 12.1 ± 6.77 11.7 ± 5.16 0.54 0.97 0.57
Stage NREM N2 (%)* 43.7 ± 5.11 37.8 ± 7.43 40.6 ± 7.48 43.9 ± 12.68 0.08 0.57 0.61
Stage NREM N3 (%) 28.3 ± 7.14 28.8 ± 7.41 27.9 ± 7.29 21.0 ± 8.20 0.11 0.08 0.17
REM sleep stage (%) 17.9 ± 3.82 21.5 ± 6.01 19.1 ± 4.80 19.4 ± 6.63 0.31 0.81 0.25
Arousal index (nº/h)* 15.0 ± 3.39 16.5 ± 9.59 14.1 ± 6.20 15.9 ± 15.48 0.80 0.47 0.94
Wake after sleep onset (minutes)* 73.9 ± 26.31 56.9 ± 36.78 91.2 ± 50.34† 102.8 ± 55.22† 0.19 0.02 0.73
Respiratory disturbance index* 5.0 ± 3.59 7.3 ± 5.58 7.6 ± 2.87 7.9 ± 4.45 0.29 0.17 0.43
Apnea-hypopnea index* 2.1 ± 2.27 2.2 ± 1.65 4.7 ± 3.72† 5.1 ± 3.24† 0.83 0.001 0.48
Periodic limb movements* 0.0 ± 0.00 0.9 ± 1.41 1.3 ± 1.82‡ 0.6 ± 1.35 0.05 0.25 0.70
Basal SpO2 (%) 95.1 ± 1.58 95.4 ± 1.35 93.9 ± 4.50 94.5 ± 2.04 0.87 0.20 0.62
Mean SpO2 (%) 95.5 ± 1.56 94.5 ± 1.22 93.7 ± 2.33
† 93.0 ± 1.64† 0.52 0.03 0.51
Lowest SpO2 (%) 88.2 ± 3.36 88.9 ± 1.58 86.7 ± 5.45 85.9 ± 5.13 0.57 0.09 0.98
Two-way analysis of variance. Reference values of polysomnography exam: TST (variable within person); sleep efficiency, the ratio of TST 
to the total amount of time spent in bed in percentage (>85% of TST); sleep latency, the length of time in minutes it takes to transits from 
wake to sleep (<30 minutes); REM sleep latency, the length of time in minutes to enter REM sleep stage (90-120 min); NREM stage N1 
sleep (up to 5% of TST); NREM stage N2 sleep (45-55% of TST); NREM stage N3 sleep (slow wave sleep or delta sleep - up to 23% of TST); 
REM sleep stage (20-25% of TST); wake after sleep onset, the amount of time in minutes spent awake after sleep has been initiated (sleep 
fragmentation - up to 30 min); wake index, the number of awakenings per hour; periodic limb movements index, number per hour of in-
voluntary movement of limbs during sleep (<15/hr); respiratory disturbance index, the index of respiratory disorders during sleep; apnea-
hypopnea index, indicates the mean number of obstructive apneas and hypopneas per hour of sleep (<5/hr); and SpO2 ≥ 90%
*Non-parametric data, square root normalization of data
†P < 0.05 compared to INS-free groups
‡P < 0.05 compared to other groups
TST: total sleep time, REM: rapid eye movement, NREM: non-rapid eye movement, SpO2: percutaneous oxygen saturation, MSP: musculo-
skeletal pain, INS: insomnia
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restorative sleep “acted” only until midday, as our INS + 
MSP group complained of worse MSP intensity at midday. 
Another hypothesis is related to the midday body tem-
perature decline. The body temperature is a biologic rhythm 
closely associated with the circadian rhythm of sleepi-
ness.23 The thermoregulatory mechanism that lowers body 
temperature and the decline in cortisol concentrations can 
promote sleep. We speculate that both could have influenced 
the increased perception of MSP at midday, so the relief of 
pain generated by sleep was evident only until the first half 
of the day. Moreover, our sample did not present daytime 
sleepiness.
Both INS and MSP are core symptoms of menopause. INS 
influences the perception of other menopausal symptoms24 such 
as MSP in our investigation. This finding, especially in rela-
tion to the somatic and psychological domains, is corrobo-
rated by another study that found INS symptoms as more 
correlated with psychological than with somatic symptoms.25 
Vasomotor symptoms, considered the hallmark indicator of 
menopause, represent a possible sleep interference. No sta-
tistical differences among groups in vasomotor symptoms 
were found in our sample.
Although no statistical difference was found in relation 
to depressive symptoms, they were, together with anxiety 
symptoms, predictive factors for menopausal symptomatol-
ogy. Anxious people, in general, are more likely to have INS 
symptoms and individuals with INS appear to have a 17-fold 
increased chance of experiencing anxiety.26
The INS groups presented higher sleep fragmentation 
(WASO). Sleep fragmentation was the most common al-
teration of sleep in chronic pain patients.27 We observed 
increased AHI and decreased mean SpO2 in the sample of 
women with INS, but despite the statistical significance of 
these findings, they do not have clinical relevance, being 
within the normal range of reference parameters. MSP did 
not influence objective sleep parameters in our investigation. 
Our postmenopausal women had impaired sleep with a 
short sleep duration of < 360 minutes on the PSG exam; 
poor sleep efficiency below 85% indicating non-restorative 
sleep; increased N1 sleep stage, indicating more superficial 
sleep; and increased WASO, evidence of sleep fragmentation. 
Lowest SpO2 was under the reference values in 90% of our 
sample. 
INS alone worsened QOL in our sample. INS may pro-
duce conditions that impair QOL such as fatigue, physical 
tiredness, mental exhaustion, irritability28 and also MSP.20 
Table 5. Generalized linear mixed model considering menopausal 
symptoms as dependent variable and symptoms of anxiety, 
depression, and insomnia severity as independent variables after 
controlling for age and hypertension (n = 62)
 β
95% CI
P value
Lower Upper
Anxiety 1.015 1.000 1.029 0.05
Depression 1.021 1.007 1.035 0.001
Pain interference 0.994 0.947 1.044 0.82
Insomnia severity 1.036 1.013 1.058 0.001
Subjective sleep quality 0.979 0.941 1.018 0.29
Sleep efficiency, PSG (%) 1.009 0.996 1.023 0.18
Stage NREM N3, PSG (%) 0.995 0.984 1.006 0.38
Wake after sleep onset, 
   PSG (minutes)
1.002 0.999 1.006 0.17
Generalized linear model, Tweedie regression
PSG: polysomnography exam, NREM: non-rapid eye movement, 
CI: confidence interval
Table 6. Generalized linear mixed model considering the 
quality of life as dependent variable and symptoms of anxiety, 
depression, menopausal symptoms, subjective sleep quality, pain 
interference, insomnia severity, and apnea-hypopnea index as 
independent variables after controlling for age and hypertension 
(n = 62)
 β
95% CI
P value
Lower Upper
Anxiety 1.001 0.993 1.010 0.80
Menopausal symptoms 0.995 0.986 1.004 0.26
Depression 0.990 0.982 0.998 0.001
Subjective sleep quality 0.998 0.977 1.020 0.87
Pain interference 0.971 0.946 0.996 0.02
Insomnia severity 0.998 0.986 1.010 0.72
Apnea-hypopnea index, 
   PSG (nº/h)
0.992 0.975 1.008 0.31
Generalized linear model, Tweedie regression
PSG: polysomnography exam, CI: confidence interval
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MSP alone was associated with lower QOL in the physical 
domain in our investigation. We found depression and pain 
interference as predictor factors for worse QOL. Menopausal 
symptoms have been shown to affect QOL in other stud-
ies, particularly in the physical domain, the highest rates of 
complaints being muscle and joint pain.29 Sleep is an essen-
tial component of good QOL.30
There are some limitations in this study that should be 
considered. First, this was a cross-sectional design, which 
does not allow the establishment of causality between fac-
tors. Second, the MSP was assessed through self-reported 
data while combined subjective and objective data may be 
more suitable for research (e.g., Quantitative Sensory Test-
ing). Third, the information about comorbidities was based 
on the participants’ self-reports. Lastly, there was no night 
of adaptation for the PSG exam, which may decrease overall 
the sleep quality of the participants from all groups.
The present results demonstrate that INS + MSP com-
bined was related to higher menopausal and anxiety symp-
toms, more sleep fragmentation, more complaints of MSP 
severity and interference, more pain sites and worse QOL. 
The presence of INS was associated to more MSP intensity 
and interference on daily function. However, the presence 
of MSP was not associated with sleep. This indicates that 
in the bidirectional association between INS and MSP in 
postmenopausal women, INS seems to play a major role, but 
investigations of the direction are warranted. Sleep man-
agement is essential in women who have developed chronic 
MSP to improve QOL and reduce the possible development of 
comorbidities, such as anxiety, depression and INS. 
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